Sejahteraraya Anugrahjaya Tbk (SRAJ) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Sejahteraraya Anugrahjaya Tbk (SRAJ) has a cash flow conversion efficiency ratio of 0.025x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rp36.75 Billion ≈ $2.15 Million USD) by net assets (Rp1.45 Trillion ≈ $84.89 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how many days can Sejahteraraya Anugrahjaya Tbk fund operations to measure how many days the company can operate on defensive assets alone.
Sejahteraraya Anugrahjaya Tbk - Cash Flow Conversion Efficiency Trend (2009–2024)
This chart illustrates how Sejahteraraya Anugrahjaya Tbk's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Sejahteraraya Anugrahjaya Tbk Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sejahteraraya Anugrahjaya Tbk ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
G Mining Ventures Corp.
TO:GMIN
|
0.069x |
|
Public Power Corporation S.A.
AT:PPC
|
0.052x |
|
AURUBIS AG UNSP.ADR 1/2
F:NDA1
|
-0.002x |
|
Shenghe Resources Holding Co Ltd
SHG:600392
|
0.024x |
|
Yunnan Chihong Zinc&Germanium Co Ltd
SHG:600497
|
0.018x |
|
UL Solutions Inc.
NYSE:ULS
|
0.164x |
|
Repligen Corporation
NASDAQ:RGEN
|
0.023x |
|
Cinda Securities Co. Ltd. A
SHG:601059
|
0.075x |
Annual Cash Flow Conversion Efficiency for Sejahteraraya Anugrahjaya Tbk (2009–2024)
The table below shows the annual cash flow conversion efficiency of Sejahteraraya Anugrahjaya Tbk from 2009 to 2024. For the full company profile with market capitalisation and key ratios, see market value of Sejahteraraya Anugrahjaya Tbk.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Rp1.83 Trillion ≈ $107.42 Million |
Rp273.25 Billion ≈ $16.01 Million |
0.149x | +395.10% |
| 2023-12-31 | Rp1.86 Trillion ≈ $108.84 Million |
Rp55.92 Billion ≈ $3.28 Million |
0.030x | -72.89% |
| 2022-12-31 | Rp1.90 Trillion ≈ $111.05 Million |
Rp210.47 Billion ≈ $12.33 Million |
0.111x | -36.44% |
| 2021-12-31 | Rp1.93 Trillion ≈ $112.94 Million |
Rp336.79 Billion ≈ $19.73 Million |
0.175x | +226.60% |
| 2020-12-31 | Rp1.75 Trillion ≈ $102.82 Million |
Rp93.88 Billion ≈ $5.50 Million |
0.054x | +26.04% |
| 2019-12-31 | Rp1.78 Trillion ≈ $104.10 Million |
Rp75.42 Billion ≈ $4.42 Million |
0.042x | +381.67% |
| 2018-12-31 | Rp1.84 Trillion ≈ $107.98 Million |
Rp16.24 Billion ≈ $951.59K |
0.009x | -6.01% |
| 2017-12-31 | Rp1.62 Trillion ≈ $95.21 Million |
Rp15.24 Billion ≈ $892.73K |
0.009x | +0.15% |
| 2016-12-31 | Rp1.72 Trillion ≈ $101.02 Million |
Rp16.14 Billion ≈ $945.82K |
0.009x | -40.66% |
| 2015-12-31 | Rp1.02 Trillion ≈ $59.48 Million |
Rp16.01 Billion ≈ $938.40K |
0.016x | +11.46% |
| 2014-12-31 | Rp1.15 Trillion ≈ $67.10 Million |
Rp16.21 Billion ≈ $949.82K |
0.014x | +122.80% |
| 2013-12-31 | Rp1.25 Trillion ≈ $73.00 Million |
Rp7.92 Billion ≈ $463.80K |
0.006x | -85.35% |
| 2012-12-31 | Rp654.08 Billion ≈ $38.33 Million |
Rp28.37 Billion ≈ $1.66 Million |
0.043x | -39.97% |
| 2011-12-31 | Rp649.42 Billion ≈ $38.05 Million |
Rp46.92 Billion ≈ $2.75 Million |
0.072x | +29.35% |
| 2010-12-31 | Rp556.74 Billion ≈ $32.62 Million |
Rp31.10 Billion ≈ $1.82 Million |
0.056x | +184.97% |
| 2009-12-31 | Rp494.99 Billion ≈ $29.00 Million |
Rp9.70 Billion ≈ $568.50K |
0.020x | -- |
About Sejahteraraya Anugrahjaya Tbk
PT Sejahteraraya Anugrahjaya Tbk provides medical services in Indonesia. The company operates and manages hospitals under the Mayapada Hospital name for neuroscience center, uro-nephrology center, cardiovascular center, gastro hepatology center, liver center, oncology center, orthopedic center, spine and arthroplasty center, obstetrics and gynecology center, internal medicine and pulmonology, ped… Read more